Trump's Pharma Shake-Up: The Great American Drug Price Bloodbath
When the Most-Favored-Nation Hammer Drops on Big Pharma
- Global pharma giants are slashing US drug prices preemptively under Trump's MFN (Most Favored Nation) policy threat — tying US prices to the lowest international benchmarks
- Bristol-Myers Squibb, Pfizer, and Sanofi lead the charge with voluntary cuts, with Eliquis (the blockbuster blood thinner) dropping from $606 to $295 per 60-pill prescription — a 51% haircut
- The policy shift signals a structural repricing of US pharmaceutical monopoly power, reshaping revenue models from "charge what the market bears" to "charge what Denmark pays"
The Cartel Collapse: Why Big Pharma Caved Without a Fight
Let's cut to the chase — US drug pricing has been the world's biggest legal arbitrage for decades. Americans paid 3-4x more for the exact same pills than Germans or Canadians. The magic trick? No government negotiation. Until now.
Trump revived the MFN rule (basically a "national price ceiling" that forces US prices to match the lowest price paid by any OECD country for the same drug). The mechanism is brutal: either you cut prices voluntarily, or face tariff retaliation via the International Emergency Economic Powers Act.
Here is the real kicker — 9 global pharma companies have already thrown in the towel. Pfizer, Sanofi, BMS, Novo Nordisk, and others agreed to price reductions on their highest-revenue drugs. BMS's Eliquis — the #1 oral anticoagulant globally — is getting slashed nearly in half. That's not a negotiation. That's a surrender.
The math is simple: if your biggest customer (US government via Medicare/Medicaid) says "match Canada's price or lose the market," you match. Margins compress, but volume survives. And with patent cliffs approaching for many blockbusters, the alternative is generics eating your lunch anyway.
The Revenue Reckoning: Who Bleeds Most from the Price Cuts
Here is where the rubber meets the road — not all pharma portfolios are built equal. The companies with concentrated exposure to US-patented small molecules take the heaviest hit.
| Company | Drug Affected | US Sales Exposure | Price Cut Magnitude | EPS Risk Estimate |
|---|---|---|---|---|
| Bristol-Myers Squibb | Eliquis | ~$12B (40% of revenue) | 51% | High (15-20% downside to 2027 EPS) |
| Pfizer | Prevnar (vaccines) & Xeljanz | ~$8B combined | 20-35% | Moderate (8-12% EPS impact) |
| Sanofi | Lantus & Aubagio | ~$5B | 25-40% | Moderate-High (10-15% hit) |
| Novo Nordisk | Ozempic | ~$4B US | 15-20% | Low-Moderate (5-8% impact post volume offset) |
The catch? Volume elasticity. In economics terms, these drugs have low price elasticity (you don't skip blood thinners because they're expensive). So a 51% price cut doesn't mean 51% less revenue — some volume gains from Medicare/Medicaid expansion will offset. But the net effect is still a structural revenue downgrade for pure-play US pharma.
Bullish Flight vs. Bearish Gravity: Two Paths Forward
The Bullish Scenario (35% probability): Volume Expansion + Pipeline Hedge
- Lower prices unlock massive new patient pools in Medicare Part D
- Biosimilars and generics remain delayed due to regulatory complexity
- Companies pivot to oncology and rare disease where pricing power survives (no MFN comparators exist for ultra-orphan drugs)
- Net result: revenue down 10-15%, but EPS only drops 5-8% due to share buybacks and cost cuts
The Bearish Scenario (65% probability): The Domino Effect + R&D Contraction
- MFN expands beyond small molecules to biologics (Humira, Opdivo, Keytruda)
- Patent cliff accelerates as companies lose pricing incentive to develop me-too drugs
- M&A collapses as acquirers cannot justify US premium synergies
- Net result: Pharma sector P/E multiples compress from 16x to 12x — a 25% de-rating
The Hidden Variable: Biosimilar Invasion
The risk nobody is talking about: voluntary price cuts do not stop biosimilar entry. If BMS drops Eliquis to $295 and a generic version launches at $150, the brand loses even that reduced price. The MFN policy effectively removes the "brand premium" protection that kept generics at bay for decades. This is a structural profit reset, not a temporary tax.
The Bottom Line
Trump just pulled the lever that every previous administration avoided — using trade policy to bend the pharma pricing curve. For investors, this means the "US pharma premium" is dead. Growth will come from volume, not pricing power. Pipeline quality matters more than market access. The companies that survive are those with drugs so novel they have no international comparator — think gene therapies, mRNA platforms, and AI-discovered targets. Everything else? It just became a utility.
댓글
댓글 쓰기